Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
United One Group Healthcare (UOG), the developer of the world's first Black Diamond Carbon & Nano Silver fusion wellness technology, announced today that it has been honored with three major industry ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Eastman Kodak faces secular decline in print as digital media erodes demand for its core printing plate business. Read why ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
New York City’s congestion pricing officially went into effect on Jan. 5, 2025, charging passenger vehicles with E-ZPass a $9 base fare to enter Manhattan below 60th Street. While commercial vehicles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback